论文部分内容阅读
目的:分析了解本院口服降糖药的用药情况,分析其合理性。方法:根据本院计算机系统提供的2015—2016年口服降糖药的销售数据,采用限定日剂量分析法,对本院近两年各类各种口服降糖药的销售金额、用药频度(DDDs)、限定日费用(DDC)和销售金额与DDDs排序比等数据进行统计分析。结果:2年来,除a-葡萄糖苷酶抑制剂的销售金额略有增长,胰岛素促泌剂类、双胍类、噻唑烷二酮类降糖药的销售金额均略有下降。a-葡萄糖苷酶抑制剂、双胍类的销售金额2年来稳居排名前二。DDDs排名前三的药物是二甲双胍片、阿卡波糖片和格列齐特缓释片。销售金额排序与DDDs的排序比在0.5—1.4之间。结论:本院口服降糖药的应用基本合理,可适当引入新型口服降糖药物以满足不同病情的需要。
Objective: To analyze and understand the medication of oral hypoglycemic agents in our hospital and analyze its rationality. Methods: Based on the sales data of oral hypoglycemic agents provided by our hospital computer system in 2015-2016, the daily dose analysis method was used to determine the sales amount, DDDs), DDC (DDC), and the ratio of sales to DDDs. Results: Sales of insulin secretagogues, biguanides, and thiazolidinediones decreased slightly in both years, except for a-glucosidase inhibitors. Sales of a-glucosidase inhibitors and biguanides topped the list in 2 years. DDDs top three drugs are metformin tablets, acarbose tablets and gliclazide sustained-release tablets. The sort of sales amount versus DDDs is between 0.5-1.4. Conclusion: The application of oral hypoglycemic agents in our hospital is reasonable and reasonable, and new oral hypoglycemic agents may be appropriately introduced to meet the needs of different conditions.